This therapy did not modify CD19 expression in KMT2A germline PDX cells (Supplementary Fig. S7C), confirming the specificity of the combined treatment in t(4;11) pro-B-ALL cells. The gene discussed is CD19; the disease is acute lymphoblastic leukemia.